- bYoRNA is developing a yeast-based bioproduction platform for the design, optimization, and manufacturing of high-quality mRNA therapeutics.
- Our patented technology aims to produce longer mRNA (up to 15,000 nt) with lower immunogenicity and higher stability, at a fraction of the current cost.
- Additional advantages include a local production (no supply chain or sovereignty issues) and the use of lowly-modified, eukaryotic nucleotides (no frameshifting).
- The first two applications are self-amplifying mRNAs and gene editing mRNAs (base editing and prime editing).